Short answer
Penumbra Inc (PEN) filed an 8-K current report with the SEC on July 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 fiscal 2026 results for quarter ended June 30, 2026.
Penumbra Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 fiscal 2026 results for quarter ended June 30, 2026
- Penumbra’s earnings press release furnished as Exhibit 99.1
- Investor focus: revenue, profitability, guidance and product trends in the accompanying release
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $390.0M, up 14.9%, with U.S. growth 17.1% outpacing international growth 7.6%
- Embolization and Access revenue $131.1M, up 20.0%, outpacing thrombectomy revenue growth of 12.5%
- Gross margin 67.9%, up 1.9 percentage points, while operating expenses rose to $223.9M
- Net income $34.8M, down from $45.3M, reflecting income tax expense of $11.4M versus $0.04M
- Pending Boston Scientific acquisition limits visibility: no full-year 2026 guidance or earnings conference call; $6.9M acquisition-related expenses incurred in SG&A
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Penumbra Inc 8-K filings
Get the next PEN 8-K as it lands
Follow PEN for push alerts, or ask the research agent what this filing means.